LONDON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical- stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in ACS Chemical Biology1 entitled: ‘Designer small molecule control system based on Minocycline induced disruption of protein-protein interaction.' 1 Cell-based therapies have become increasingly complex and are being used to treat a wide range of diseases such as cancer and autoimmunity. However, c ...